These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 36193677)

  • 21. Trends in epidemiology, treatment, and survival of hepatocellular carcinoma patients between 1998 and 2009: an analysis of 1066 cases of a German HCC Registry.
    Weinmann A; Koch S; Niederle IM; Schulze-Bergkamen H; König J; Hoppe-Lotichius M; Hansen T; Pitton MB; Düber C; Otto G; Schuchmann M; Galle PR; Wörns MA
    J Clin Gastroenterol; 2014 Mar; 48(3):279-89. PubMed ID: 24045276
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hepatocellular carcinoma: surgical perspectives beyond the barcelona clinic liver cancer recommendations.
    Guglielmi A; Ruzzenente A; Conci S; Valdegamberi A; Vitali M; Bertuzzo F; De Angelis M; Mantovani G; Iacono C
    World J Gastroenterol; 2014 Jun; 20(24):7525-33. PubMed ID: 24976693
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adherence to Barcelona Clinic Liver Cancer guidelines in field practice: Results of Progetto Epatocarcinoma Campania.
    Guarino M; Tortora R; de Stefano G; Coppola C; Morisco F; Salomone Megna A; Izzo F; Nardone G; Piai G; Adinolfi LE; D'Adamo G; Gaeta GB; Messina V; Francica G; De Girolamo V; Coppola N; Persico M; Di Costanzo GG;
    J Gastroenterol Hepatol; 2018 May; 33(5):1123-1130. PubMed ID: 28994145
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inpatient Specialty-Level Palliative Care Is Delivered Late in the Course of Hepatocellular Carcinoma and Associated With Lower Hazard of Hospital Readmission.
    Woodrell CD; Goldstein NE; Moreno JR; Schiano TD; Schwartz ME; Garrido MM
    J Pain Symptom Manage; 2021 May; 61(5):940-947.e3. PubMed ID: 33035651
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pivoting to telemedicine in a single-day multidisciplinary liver tumor clinic during COVID-19: the Texas Liver Tumor Center experience.
    Crow KS; Poordad FF; Halff GA; Cigarroa FG; Tsai E; Infante IV; Arora SP
    Ann Palliat Med; 2023 Nov; 12(6):1310-1317. PubMed ID: 37953220
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Transarterial radioembolization versus chemoembolization for the treatment of hepatocellular carcinoma (TRACE): study protocol for a randomized controlled trial.
    Seinstra BA; Defreyne L; Lambert B; Lam MG; Verkooijen HM; van Erpecum KJ; van Hoek B; van Erkel AR; Coenraad MJ; Al Younis I; van Vlierberghe H; van den Bosch MA
    Trials; 2012 Aug; 13():144. PubMed ID: 22913492
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Asian consensus workshop report: expert consensus guideline for the management of intermediate and advanced hepatocellular carcinoma in Asia.
    Han KH; Kudo M; Ye SL; Choi JY; Poon RT; Seong J; Park JW; Ichida T; Chung JW; Chow P; Cheng AL
    Oncology; 2011; 81 Suppl 1():158-64. PubMed ID: 22212951
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Current and future treatments for hepatocellular carcinoma.
    Schlachterman A; Craft WW; Hilgenfeldt E; Mitra A; Cabrera R
    World J Gastroenterol; 2015 Jul; 21(28):8478-91. PubMed ID: 26229392
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Management of hepatocellular in the United States.
    Mokdad AA; Hester CA; Singal AG; Yopp AC
    Chin Clin Oncol; 2017 Apr; 6(2):21. PubMed ID: 28482674
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Risk factors of mortality in the patients with hepatocellular carcinoma: A multicenter study in Indonesia.
    Jasirwan COM; Hasan I; Sulaiman AS; Lesmana CRA; Kurniawan J; Kalista KF; Nababan SH; Gani RA
    Curr Probl Cancer; 2020 Feb; 44(1):100480. PubMed ID: 31130257
    [TBL] [Abstract][Full Text] [Related]  

  • 31. New Approaches in Locoregional Therapies for Hepatocellular Carcinoma.
    Memeo R; de Blasi V; Cherkaoui Z; Dehlawi A; De' Angelis N; Piardi T; Sommacale D; Marescaux J; Mutter D; Pessaux P
    J Gastrointest Cancer; 2016 Sep; 47(3):239-46. PubMed ID: 27270711
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Interventional treatment for unresectable hepatocellular carcinoma.
    Murata S; Mine T; Sugihara F; Yasui D; Yamaguchi H; Ueda T; Onozawa S; Kumita S
    World J Gastroenterol; 2014 Oct; 20(37):13453-65. PubMed ID: 25309076
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Attitudes and Beliefs Toward Supportive and Palliative Care Referral Among Hematologic and Solid Tumor Oncology Specialists.
    Hui D; Park M; Liu D; Reddy A; Dalal S; Bruera E
    Oncologist; 2015 Nov; 20(11):1326-32. PubMed ID: 26417037
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Radioembolisation with yttrium‒90 microspheres versus sorafenib for treatment of advanced hepatocellular carcinoma (SARAH): study protocol for a randomised controlled trial.
    Vilgrain V; Abdel-Rehim M; Sibert A; Ronot M; Lebtahi R; Castéra L; Chatellier G;
    Trials; 2014 Dec; 15():474. PubMed ID: 25472660
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and effectiveness of chemoembolization with drug-eluting beads for advanced-stage hepatocellular carcinoma.
    Kalva SP; Pectasides M; Liu R; Rachamreddy N; Surakanti S; Yeddula K; Ganguli S; Wicky S; Blaszkowsky LS; Zhu AX
    Cardiovasc Intervent Radiol; 2014 Apr; 37(2):381-7. PubMed ID: 23754191
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Locoregional therapies for hepatocellular carcinoma: which patients are most likely to gain a survival advantage?
    Mahady SE; Charlton B; Fitzgerald P; Koorey DJ; Perry JF; Waugh RC; McCaughan GW; Strasser SI
    J Gastroenterol Hepatol; 2010 Jul; 25(7):1299-305. PubMed ID: 20594260
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Outpatient palliative care and thoracic medical oncology: Referral criteria and clinical care pathways.
    Caraceni A; Lo Dico S; Zecca E; Brunelli C; Bracchi P; Mariani L; Garassino MC; Vitali M
    Lung Cancer; 2020 Jan; 139():13-17. PubMed ID: 31704278
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Management and outcomes among patients with sarcomatoid hepatocellular carcinoma: A population-based analysis.
    Wu L; Tsilimigras DI; Farooq A; Hyer JM; Merath K; Paredes AZ; Mehta R; Sahara K; Shen F; Pawlik TM
    Cancer; 2019 Nov; 125(21):3767-3775. PubMed ID: 31299092
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Real Life Treatment of Hepatocellular Carcinoma: Impact of Deviation from Guidelines for Recommended Therapy.
    Alkhatib A; Gomaa A; Allam N; Rewisha E; Waked I
    Asian Pac J Cancer Prev; 2015; 16(16):6929-34. PubMed ID: 26514470
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effectiveness of locoregional therapies versus supportive care in maintaining survival within the Milan criteria in patients with hepatocellular carcinoma.
    Dhanasekaran R; Khanna V; Kooby DA; Spivey JR; Parekh S; Knechtle SJ; Carew JD; Kauh JS; Kim HS
    J Vasc Interv Radiol; 2010 Aug; 21(8):1197-204; quiz 204. PubMed ID: 20656222
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.